Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human/Mouse/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-RXFP1 (673-757) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:2000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
RXFP1 |
Gene ID: |
59350 |
Uniprot ID: |
RXFP1_HUMAN |
Immunogen Region: |
673-757 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 673-757 of human RXFP1 (NP_067647.2). |
Immunogen Sequence: |
NSALNPILYTLTTRPFKEMI HRFWYNYRQRKSMDSKGQKT YAPSFIWVEMWPLQEMPPEL MKPDLFTYPCEMSLISQSTR LNSYS |
Tissue Specificity | Expressed in the brain, kidney, testis, placenta, uterus, ovary, adrenal, prostate, skin and heart. Not detected in spleen. |
Function | Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activity of a phosphodiesterase that degrades cAMP. |
Protein Name | Relaxin Receptor 1Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 7Relaxin Family Peptide Receptor 1 |
Database Links | Reactome: R-HSA-418555Reactome: R-HSA-444821 |
Cellular Localisation | Cell MembraneMulti-Pass Membrane Protein |
Alternative Antibody Names | Anti-Relaxin Receptor 1 antibodyAnti-Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 7 antibodyAnti-Relaxin Family Peptide Receptor 1 antibodyAnti-RXFP1 antibodyAnti-LGR7 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance